571 related articles for article (PubMed ID: 11750052)
1. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias.
Amare PS; Baisane C; Saikia T; Nair R; Gawade H; Advani S
Cancer Genet Cytogenet; 2001 Dec; 131(2):125-34. PubMed ID: 11750052
[TBL] [Abstract][Full Text] [Related]
2. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
3. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.
Primo D; Tabernero MD; Rasillo A; Sayagués JM; Espinosa AB; Chillón MC; Garcia-Sanz R; Gutierrez N; Giralt M; Hagemeijer A; San Miguel JF; Orfao A
Leukemia; 2003 Jun; 17(6):1124-9. PubMed ID: 12764379
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
Song YQ; Li W; Kong LH; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
[TBL] [Abstract][Full Text] [Related]
5. Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings.
Akel S; Kolialexi A; Mavrou A; Metaxotou C; Loukopoulos D; Yataganas X
Clin Lab Haematol; 2002 Dec; 24(6):361-7. PubMed ID: 12452817
[TBL] [Abstract][Full Text] [Related]
6. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements.
Pelz AF; Kröning H; Franke A; Wieacker P; Stumm M
Ann Hematol; 2002 Mar; 81(3):147-53. PubMed ID: 11904740
[TBL] [Abstract][Full Text] [Related]
7. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells.
Yanagi M; Shinjo K; Takeshita A; Tobita T; Yano K; Kobayashi M; Terasaki H; Naoe T; Ohnishi K; Ohno R
Leukemia; 1999 Apr; 13(4):542-52. PubMed ID: 10214860
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of minimal residual disease in patients with chronic myeloid leukaemia on IFN-alpha 2b therapy using conventional cytogenetics and fluorescence in situ hybridization.
Talwar R; Choudhry VP; Jobanputra V; Kucheria K
Natl Med J India; 2002; 15(4):195-8. PubMed ID: 12296472
[TBL] [Abstract][Full Text] [Related]
9. RARA fluorescence in situ hybridization overcomes the drawback of PML/RARA fluorescence in situ hybridization in follow-up of acute promyelocytic leukemia.
Lee DS; Lee YS; Kim YR; Han KS; Park KU; She CJ; Kim EC; Park SY; Cho HI
Cancer Genet Cytogenet; 2002 Dec; 139(2):104-8. PubMed ID: 12550769
[TBL] [Abstract][Full Text] [Related]
10. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
Duan MH; Li H; Cai H
Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
[TBL] [Abstract][Full Text] [Related]
11. A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias.
Cox MC; Maffei L; Buffolino S; Del Poeta G; Venditti A; Cantonetti M; Aronica G; Aquilina P; Masi M; Amadori S
Am J Clin Pathol; 1998 Jan; 109(1):24-31. PubMed ID: 9426514
[TBL] [Abstract][Full Text] [Related]
12. [Fluorescent in-situ hybridization technique (FISH) in the diagnosis of Philadelphia translocation in chronic myeloid leukemia].
Martinet D; Mühlematter D; Jotterand Bellomo M
Schweiz Med Wochenschr; 1996 May; 126(20):855-63. PubMed ID: 8685681
[TBL] [Abstract][Full Text] [Related]
13. [Clonal chromosome abnormalities in malignant hematological diseases using fluorescence in situ hybridization].
Soto-Quintana M; Rojas-Atencio A; Chirino H; Alvarez-Nava F; Pineda-Del Villar L; Urdaneta K; González-Ferrer S; González R
Invest Clin; 1998 Jun; 39(2):85-96. PubMed ID: 9707920
[TBL] [Abstract][Full Text] [Related]
14. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
Itoh T; Tamura S; Takemoto Y; Kakishita E
Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
[TBL] [Abstract][Full Text] [Related]
15. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay.
Preudhomme C; Chams-Eddine L; Roumier C; Duflos-Grardel N; Denis C; Cosson A; Fenaux P
Leukemia; 1999 May; 13(5):818-23. PubMed ID: 10374889
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
Wu B; Zhou S; Song L; Liu X
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
[TBL] [Abstract][Full Text] [Related]
17. Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra signals.
Mohr B; Bornhäuser M; Platzbecker U; Freiberg-Richter J; Naumann R; Prange-Krex G; Mohm J; Kroschinsky F; Ehninger G; Thiede C
Cancer Genet Cytogenet; 2001 Jun; 127(2):111-7. PubMed ID: 11425449
[TBL] [Abstract][Full Text] [Related]
18. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
[TBL] [Abstract][Full Text] [Related]
19. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy.
Tchirkov A; Giollant M; Tavernier F; Briançon G; Tournilhac O; Kwiatkowski F; Philippe P; Choufi B; Deméocq F; Travade P; Malet P
Br J Haematol; 1998 Jun; 101(3):552-7. PubMed ID: 9633901
[TBL] [Abstract][Full Text] [Related]
20. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.
Chomel JC; Brizard F; Veinstein A; Rivet J; Sadoun A; Kitzis A; Guilhot F; Brizard A
Blood; 2000 Jan; 95(2):404-8. PubMed ID: 10627442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
